- Home
- TLPH vs SNTI Comparison
TLPH vs SNTI Comparison
Compare TLPH & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- SNTI
- Stock Information
- Founded
- TLPH 2005
- SNTI 2016
- Country
- TLPH United States
- SNTI United States
- Employees
- TLPH N/A
- SNTI N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- SNTI Health Care
- Exchange
- TLPH Nasdaq
- SNTI Nasdaq
- Market Cap
- TLPH 64.7M
- SNTI 53.6M
- IPO Year
- TLPH 2011
- SNTI N/A
- Fundamental
- Price
- TLPH $1.34
- SNTI $1.66
- Analyst Decision
- TLPH Strong Buy
- SNTI Strong Buy
- Analyst Count
- TLPH 1
- SNTI 3
- Target Price
- TLPH $6.00
- SNTI $9.67
- AVG Volume (30 Days)
- TLPH 318.3K
- SNTI 89.7K
- Earning Date
- TLPH 11-12-2025
- SNTI 11-13-2025
- Dividend Yield
- TLPH N/A
- SNTI N/A
- EPS Growth
- TLPH N/A
- SNTI N/A
- EPS
- TLPH N/A
- SNTI N/A
- Revenue
- TLPH $28,000.00
- SNTI N/A
- Revenue This Year
- TLPH N/A
- SNTI N/A
- Revenue Next Year
- TLPH $14,533.26
- SNTI $150.00
- P/E Ratio
- TLPH N/A
- SNTI N/A
- Revenue Growth
- TLPH N/A
- SNTI N/A
- 52 Week Low
- TLPH $0.38
- SNTI $1.26
- 52 Week High
- TLPH $1.45
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- TLPH 57.82
- SNTI 45.41
- Support Level
- TLPH $1.01
- SNTI $1.44
- Resistance Level
- TLPH $1.35
- SNTI $1.99
- Average True Range (ATR)
- TLPH 0.11
- SNTI 0.16
- MACD
- TLPH -0.01
- SNTI -0.06
- Stochastic Oscillator
- TLPH 80.49
- SNTI 37.76
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.